Quinpramine is a novel compound effective in ameliorating brain autoimmune disease.
Acridine-iminodibenzyl chimeric compounds were previously introduced as a class of cholesterol-redistributing substances with antiprion effects. Here, we show that administration of the lead compound quinpramine to mice with experimental autoimmune encephalitis, an animal model of multiple sclerosis (MS), significantly ameliorates disease in preventive and therapeutic paradigms. Quinpramine treatment decreased the number of inflammatory CNS lesions, antigen-specific T-cell proliferation, and pro-inflammatory cytokines IFNgamma and IL-17. Quinpramine is thus an immunoregulatory drug that is a candidate pharmaceutical for MS.
Singh
Mahendra P
MP
Department of Neurology, University of Texas Southwestern, Dallas, USA.
Meyer zu Hörste
Gerd
G
Hu
Wei
W
Mausberg
Anne K
AK
Cravens
Petra D
PD
Eagar
Todd
T
Löber
Stefan
S
Klingenstein
Ralf
R
Gmeiner
Peter
P
Korth
Carsten
C
Kieseier
Bernd C
BC
Stüve
Olaf
O
D000818:Animals; D049109:Cell Proliferation / Q000187:drug effects; D016207:Cytokines / Q000378:metabolism; D004195:Disease Models, Animal; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000139:chemically induced / Q000188:drug therapy*; D005260:Female; D006023:Glycoproteins; D051379:Mice; D008810:Mice, Inbred C57BL; D063308:Myelin-Oligodendrocyte Glycoprotein; D010446:Peptide Fragments; D011806:Quinolinium Compounds / Q000627:therapeutic use*; D013601:T-Lymphocytes / Q000187:drug effects
D016207:Cytokines; D006023:Glycoproteins; D063308:Myelin-Oligodendrocyte Glycoprotein; D010446:Peptide Fragments; D011806:Quinolinium Compounds; C445081:myelin oligodendrocyte glycoprotein (35-55)